Intrinsic protein flexibility in regulation of cell proliferation: Advantages for signaling and opportunities for novel therapeutics

Advances in Experimental Medicine and Biology

Volumn 725, Issue , 2012, Pages 27-49

  Follis, Ariele Viacava ^a   Galea, Charles A ^b   Kriwacki, Richard W ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; DOXYCYCLINE; MAX PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; THREONINE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; COMPLEX FORMATION; GENE DISRUPTION; GENE OVEREXPRESSION; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EUKARYOTA; MAMMALIA;

AMINO ACID SEQUENCE; ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84859517054     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0659-4_3     Document Type: Article

References (130)

1. Receveur-Brechot V, BourhisJM, Uversky VN et al. Assessing protein disorder and induced folding. Proteins 2006; 62:24-45.
2. Mittag T, Forman-Kay JD. Atomic-level characterization of disordered protein ensembles. Curr Opin Struct Biol 2007; 17:3-14.
3. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005: 6:197-208.
4. Obradovic Z, Peng K, Vucetic S et al. Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins 2005: 61 Suppl 7:176-182.
5. Nair SK, Burley SK. X-ray structures of Myc-Maxand Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003: 112:193-205.
6. Follis AV, Hammoudeh DI, Wang H et al. Structural rationale for the coupled binding and unfolding ofthe c-Myc oncoprotein by small molecules. Chem Biol 2008: 15:1149-1155.
7. Hammoudeh DI, Follis AV, Prochownik EV et al.Multiple independent binding sites for small molecule inhibitors on the c-Myc oncoprotein. J Am Chem Soc 2009: 131:7390-7401.
8. Yin X, Giap C, Lazo JS et al. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003; 22:6151-6159.
9. Clark SS, McLaughlinJ, Crist WM et al. Unique forms of theabl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987: 235:85-88.
10. Chu I, Sun J, Arnaout A et al. P27Phosphorylation by src regulates inhibition ofcyclin E-Cdk2. Cell 2007; 128:281-294.
11. Kiessling A, Sperl B, Hollis A et al. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006; 13:745-751.
12. Dunker AK, Brown CJ, Lawson JD et al. Intrinsic disorder and protein function. Biochemistry 2002: 41:6573-6582.
13. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27:527-533.
14. Uversky VN.Nativelyunfoldedproteins: apointwhere biology waits forphysics. Protein Sci2002:11:739-756.
15. Oldfield CJ, Cheng Y, Cortese MS et al. Comparing and combining predictors of mostly disordered proteins. Biochemistry 2005; 44:1989-2000.
16. A list of currently available disorder predictors is available on the DisProt web site at http://www.disprot.org/predictors.php.
17. Dunker AK, Obradovic Z, Romero P et al. Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform 2000; 11:161-171.
18. Ward JJ, Sodhi JS, McGufEn LJ et al. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004; 337:635-645.
19. Xie H, Vucetic S, Iakoucheva LM et al. Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J Proteome Res 2007; 6:1882-1898.
20. Vucetic S, Xie H, Iakoucheva LM et al. Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes and coding sequence diversities correlated with long disordered regions. J Proteome Res 2007; 6:1899-1916.
21. Liu J, Perumal NB, Oldfield CJetal. Intrinsic disorder in transcription factors. Biochemistry 2006; 45:6873-6888.
22. Iakoucheva LM, Brown CJ, Lawson JD et al. Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol 2002; 323:573-584.
23. Gsponer J, Futschik ME, Teichmann SA et al. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science 2008; 322:1365-1368.
24. Vavouri T, Semple JI, Garcia-Verdugo R et al. Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell 2009; 138:198-208.
25. Ayed A, Mulder FA, Yi GS et al. Latent and active p53 are identical in conformation. Nat Struct Biol 2001; 8:756-760.
26. Hoh JH. Functional protein domains from the thermally driven motion ofpolypeptide chains: a proposal. Proteins 1998; 32:223-228.
27. Tskhovrebova L, Trinick J. Titin: properties and family relationships. Nat Rev Mol Cell Biol2003; 4:679-689.
28. Alber F, Dokudovskaya S, Veenhoff LM et al. The molecular architecture of the nuclear pore complex. Nature 2007; 450:695-701.
29. Spolar RS, Record MT Jr. Coupling oflocal folding to site-speciic binding ofproteins to DNA. Science 1994; 263:777-784.
30. Demarest SJ, Martinez-Yamout M, Chung J et al. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 2002; 415:549-553.
31. Lacy ER, Filippov I, Lewis WS et al. P27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol 2004; 11:358-364.
32. Tompa P, Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci 2008; 33:2-8.
33. Frederick KK, Marlow MS, Valentine KG et al. Conformational entropy in molecular recognition by proteins. Nature 2007; 448:325-329.
34. Leung DW, Rosen MK. The nucleotide switch in Cdc42 modulates coupling betweenthe GTPase-binding and allosteric equilibria of Wiskott-Aldrich syndrome protein. Proc Natl Acad Sci USA 2005; 102:5685-5690.
35. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 1999; 293:321-331.
36. Kriwacki RW, Hengst L, Tennant L etal. Structural studies ofp21(waf1/cip1/sdi1) in the free and Cdk2-bound state:Conformational disordermediatesbinding diversity. Proc Natl AcadSci USA 1996;93:11504-11509.
37. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14:159-169.
38. Joerger AC, Fersht AR. Structural Biology of the Tumor Suppressor p53. Annu Rev Biochem 2008; 77:557-582.
39. DunkerAK, Cortese MS, Romero P etal. Flexible nets. The roles ofintrinsic disorder inproteininteraction networks. Febs J 2005; 272:5129-5148.
40. Kim PM, Sboner A, Xia Y etal. The role of disorder in interaction networks: a structural analysis. Mol Syst Biol 2008; 4:179-185.
41. Schnell S, Fortunato S, Roy S. Is the intrinsic disorder ofproteins the cause ofthe scale-free architecture of protein-protein interaction networks? Proteomics 2007; 7:961-964.
42. Bode AM,Dong Z. Post-translationalmodiicationofp53 intumorigenesis. NatRevCancer2004; 4:793-805.
43. Grimmler M, Wang Y, Mund T et al. Cdk-inhibitory activity and stability of p27(Kip1) are directly regulated by oncogenic tyrosine kinases. Cell 2007; 128:269-280.
44. Tompa P, Prilusky J, Silman I et al. Structural disorder serves as a weak signal for intracellular protein degradation. Proteins 2007; 71:903-909.
45. Tsvetkov P, Asher G, Paz A et al. Operational deinition of intrinsically unstructured protein sequences based on susceptibility to the 20S proteasome. Proteins 2007; 70:1357-1366.
46. LavinMF,GuevenN. Thecomplexity ofp53 stabilization and activation. Cell Death Differ2006; 13:941-950.
47. Tsvetkov P, Reuven N, Shaul Y. The nanny model for IDPs. Nat Chem Biol 2009; 5:778-781.
48. Shoemaker BA, Portman JJ, Wolynes PG. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc Natl Acad Sci USA 2000: 97:8868-8873.
49. Sugase K, Dyson HJ, Wright PE. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 2007; 447:1021-1025.
50. Huang Y, Liu Z. Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the "fly-casting" mechanism. J Mol Biol 2009: 393:1143-1159.
51. Hilser VJ, Thompson EB. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc Natl Acad Sci USA 2007; 104:8311-8315.
52. Morgan DO. Principles of CDK regulation. Nature 1995: 374:131-134.
53. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
54. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004: 18:2699-2711.
55. Poon RY, Hunter T. Expression ofa novel form ofp21Cip1/Waf1 in UV-irradiated and transformed cells. Oncogene 1998; 16:1333-1343.
56. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) andp27(Kip 1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11:492-503.
57. Waga S, Hannon GJ, Beach D et al. The p21 inhibitor ofcyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994: 369:574-578.
58. Watanabe H, Pan ZQ, Schreiber-Agus N et al. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1998; 95:1392-1397.
59. Montagnoli A, Fiore F, Eytan E et al. Ubiquitination of p27 isregulated by Cdk-dependent phosphorylation andtrimeric complex formation. Genes Dev 1999: 13:1181-1189.
60. Nguyen H, Gitig DM, Koff A. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent onCDK2 activity and the proteasome. Mol Cell Biol 1999; 19:1190-1201.
61. Kamura T, Hara T, Kotoshiba S et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100:10231-10236.
62. Matsuoka S, Edwards MC,Bai C et al. P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family,is a candidate tumor suppressor gene. Genes Dev 1995: 9:650-652.
63. Russo AA, Jeffrey PD, Patten AK et al. Crystal structure ofthe p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996: 382:325-331.
64. Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev 2001; 101:2511-2526.
65. Lacy ER, Wang Y, Post J et al. Molecular Basis for the Specificity of p27 Toward Cyclin-dependent Kinases that Regulate Cell Division. J Mol Biol 2005; 349:764-773.
66. Adkins JN, LumbKJ. Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins 2002; 46:1-7.
67. Bienkiewicz EA, Adkins JN, Lumb KJ. Functional consequences of preorganized helical structure in the intrinsically disordered cell-cycle inhibitor p27(Kip1). Biochemistry 2002: 41:752-759.
68. Prilusky J, Felder CE, Zeev-Ben-Mordehai T et al. Foldlndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 2005: 21:3435-3438.
69. Dosztanyi Z, Csizmok V, Tompa P et al. IUPred: web server for the prediction ofintrinsically unstructured regions ofproteins based on estimated energy content. Bioinformatics 2005: 21:3433-3434.
70. Romero P, Obradovic Z, Li X et al. Sequence complexity ofdisordered protein. Proteins 2001: 42:38-48.
71. Harper JW, Elledge S, Keyomarsi K et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6:387-400.
72. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994: 78:59-66.
73. Hengst L, Dulic V, Slingerland JM et al. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994; 91:5291-5295.
74. Sivakolundu SG, Bashford D, Kriwacki RW. Disorderedp27(Kip 1) Exhibits Intrinsic Structure Resembling the Cdk2/Cyclin A-bound Conformation. J Mol Biol 2005: 353:1118-1128.
75. Galea CA, Nourse A, Wang Y et al. Role of intrinsic flexibility in signal transduction mediated by the cell cycle regulator, p27(Kip1). J Mol Biol 2007: 376:827-838.
76. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002: 8:1076-1078.
77. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-267.
78. Prakash S, Tian L,Ratliff KS etal. An unstructured initiation site is required for efficient proteasome-mediated degradation. Nat Struct Mol Biol 2004; 11:830-837.
79. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008: 8:446-458.
80. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008: 8:976-990.
81. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755-2766.
82. Bahram F, von der Lehr N, Cetinakaya C et al c-Myc hot spot mutations in lymphomas result in ineficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95:2104-2110.
83. NeelBG, Hayward WS, RobiinsonHLet al. Avian leukosis virus-induced tumors have common proviral intregration sites and synthesize discrete new RNAs: oncogenesis by promoter. Cell 1981; 23:323-334.
84. Steffen D. Proviruses are adjacent to c-myc in some murine leukemia virus-induced lymphomas. Proc Natl Acad Sci USA 1984; 81:2097-2101.
85. Crews S, Barth R, Hood L et al. Mouse c-myc oncogene is located on chromosome 15 and traslocated to chromosome 12 in plasmacytomas. Science 1982; 218:1319-1321.
86. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20:5595-5610.
87. Collins S, Groudine M. Ampliication of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 1982; 298:679-681.
88. Alitalo K, Shwab M, Lin CC et al. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 1983; 80:1707-1711.
89. Leder A, Pattengale PK, Kuo A et al. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986; 45:485-495.
90. Weng AP, Millholland JM, Yashiro-Ohtani Y et al. C-Myc is animportant direct target ofNotch1 inT-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20:2096-2109.
91. Hann SR. Role of posttranslational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Sem Cancer Biol 2006; 16:288-302.
92. Vervoorts J, Luscher-Firzlaff JM, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006; 281:34725-34729.
93. Dang CV. c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 1999; 19:1-11.
94. Dang CV, O'Donnell KA, Zeller KI etal.The c-Myc target gene network. SemCancer Biol 2006; 16:253-264.
95. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 1999; 18:2934-2941.
96. Luscher B, Eisenman RN. New light on Myc and Myb. Part I. Myc. Genes Dev 1990; 4:2025-2035.
97. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992; 61:809-860.
98. Grandori C, Gomez-Roman N, Felton-Edkins ZA et al c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 2005; 7:311-318.
99. Stone J, de Lange T, Ramsay G et al. Definition of regions inhuman c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 1987; 7:1697-1709.
100. Kato GJ, Barrett J, Villa-Garcia M et al. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 1990; 10:5914-5920.
101. Blackwell TK, Kretzner L, Blackwood EM et al. Sequence-speciicDNA binding by the c-Myc protein. Science 1990; 250:1149-1151.
102. McMahonSB,WoodMA, ColeMD. The essentialcofactorTRRAP recruits thehistoneacetyltransferase hGCN5 to c-Myc. Mol Cell Biol 2000; 20:556-562.
103. Grace Cheng SW, Davles KP, Yung E et al. C-MYC interacts with INI1/hSNF5 and requires the SWI/ SNF complex for transactivationfunction. Nat Genet 1999; 22:102-105.
104. Eberhardy SR, Farnham PJ. C-Myc mediates activation of the cad promoter via a postRNA polymerase II recruitment mechanism. J Biol Chem 2001; 276:48562-48571.
105. Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the inal step in the transcriptional activation of the cad promoter. J Biol Chem 2002; 277:40156-40162.
106. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-speciic DNA-binding complex with Myc. Science 1991; 251:1211-1217.
107. Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev 1992; 2:227-235.
108. Amati B, Brooks MW, Levy N et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993; 72:233-245.
109. Lavigne P, Crump MP, Gagne SM et al. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Maxheterodimeric leucine zipper. J Mol Biol 1998; 281:165-181.
110. Mao DY, Watson JD, Yan PS et al. Analysis of Myc bound loci identiied by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 2003; 13:882-886.
111. Wang YH, Liu S, Zhang G et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7:R220-R228.
112. Balaji KC, Koul H, Mitra S et al. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 1997; 50:1007-1015.
113. Siddiqui-Jain A, Grand CL, Bearss DJ et al. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA 2002; 99:11593-11598.
114. Mo H, Henriksson M. Identiication ofsmall molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA 2006: 103:6344-6349.
115. Claasen G, Brin E, Crogan-Grundy C et al. Selective activation of apoptosis by a novel set of 4-aryl-3-(3-aryl-1-oxo-2- propenyl)-2(1H)- quinolinones through a Myc-dependent pathway. Cancer Lett 2008; 274:243-249.
116. GiorelloL, ClericoL, PescaroloMP etal. Inhibitionofcancercellgrowthandc- Myctranscriptionalactivity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 1998: 58:3654-3659.
117. Berg T, Cohen SB, Desharnais J et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-inducedtransformationofchickenembryoibroblasts. Proc NatAcadSci USA2002: 99:3830-3835.
118. Xu Y, Shi J, Yamamoto N et al. A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem 2006; 14:2660-2673.
119. KiesslingA,WiesingerR, SperlBetal. Selective inhibition of c-Myc/Max dimerizationby apyrazolo[1,5-a] pyrimidine. ChemMedChem 2007; 2:627-630.
120. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticanc 2004; 4:289-302.
121. Ponzielli R, Katz S, Barsyte-Lovejoy D et al. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005; 41:2485-2501.
122. Soucek L, Whitield J, Martins CPet al. Modelling Myc inhibition as a cancer therapy. Nature 2008: 455:679-683.
123. Soucek L, Helmer-Citterich M, Sacco A et al. Design and properties ofa Myc derivative that eficiently homodimerizes. Oncogene 1998; 17:2463-2472.
124. Iakoucheva LM, Brown CJ, Lawson JD et al. Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol 2002; 323:573-584.
125. Wang H, Hammoudeh DI, Follis AV et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007; 6:2399-2408.
126. Mustata G, Follis AV, Hammoudeh DI et al. Discovery of novel myc-max heterodimer disruptors with a 3-dimensional pharmacophore model. J Med Chem 2009; 52:1247-1250.
127. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000: 41:415-427.
128. Uversky VN, Oldield CJ, Dunker AK. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J Mol Recognit 2005; 18:343-384.
129. Mittag T, Orlicky S, Choy WY et al. Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor. Proc Natl Acad Sci USA 2008; 105:17772-17777.
130. MittagT, Kay LE, Forman-Kay JD. Protein dynamics and conformational disorder inmolecularrecognition. J Mol Recognit 2010; 23:105-116.